Patents by Inventor Roberto A. Maldonado

Roberto A. Maldonado has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN
    Publication number: 20200360350
    Abstract: This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 19, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
    Patent number: 10668053
    Abstract: This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 2, 2020
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
    Publication number: 20200113874
    Abstract: Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
    Type: Application
    Filed: August 26, 2019
    Publication date: April 16, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS
    Publication number: 20200101154
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Application
    Filed: August 8, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS
    Publication number: 20200101155
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Application
    Filed: September 4, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • METHODS PROVIDING A THERAPEUTIC MACROMOLECULE AND SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT LOCALLY AND CONCOMITANTLY TO REDUCE BOTH TYPE 1 AND TYPE IV HYPERSENSITIVITY
    Publication number: 20200078341
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Application
    Filed: June 11, 2019
    Publication date: March 12, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • METHODS COMPRISING DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES
    Publication number: 20200069660
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Application
    Filed: June 6, 2019
    Publication date: March 5, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells
    Patent number: 10441651
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: October 15, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
    Patent number: 10434088
    Abstract: Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 8, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
    Patent number: 10420835
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 24, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Methods comprising dosing combinations for reducing undesired humoral immune responses
    Patent number: 10357483
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
    Patent number: 10357482
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES
    Publication number: 20190076522
    Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
    Type: Application
    Filed: August 6, 2018
    Publication date: March 14, 2019
    Applicant: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
  • Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
    Patent number: 10039822
    Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: August 7, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells
    Patent number: 10004802
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 26, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers for inducing regulatory B cells
    Patent number: 9993548
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: June 12, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
    Patent number: 9987354
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 5, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
    Publication number: 20160279234
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: March 4, 2016
    Publication date: September 29, 2016
    Applicant: SELECTA BIOSCIENCES, INC.
    Inventors: TAKASHI KEI KISHIMOTO, CHRISTOPHER FRASER, ROBERTO A. MALDONADO
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
    Publication number: 20160256401
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Application
    Filed: March 4, 2016
    Publication date: September 8, 2016
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS
    Publication number: 20160243253
    Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 25, 2016
    Inventors: Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado